Open AccessStevens–Johnson S yndrome associated with mogamulizumab treatment of adult T ‐cell leukemia / lymphoma
Author(s) -
Ishida Takashi,
Ito Asahi,
Sato Fumihiko,
Kusumoto Shigeru,
Iida Shinsuke,
Inagaki Hiroshi,
Morita Akimichi,
Akinaga Shiro,
Ueda Ryuzo
Publication year - 2013
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12116
Subject(s) - lymphoma , leukemia , medicine , immunology , cancer research
We report an adult T ‐cell leukemia/lymphoma patient suffering from S tevens– J ohnson S yndrome ( SJS ) during mogamulizumab (humanized anti‐ CCR 4 monoclonal antibody) treatment. There was a durable significant reduction of the CD 4 + CD 25 high FOXP 3 + regulatory T ( T reg) cell subset in the patient's PBMC , and the affected inflamed skin almost completely lacked FOXP 3‐positive cells. This implies an association between reduction of the T reg subset by mogamulizimab and occurrence of SJS . The present case should contribute not only to our understanding of human pathology resulting from therapeutic depletion of T reg cells, but also alert us to the possibility of immune‐related severe adverse events such as SJS when using mogamulizumab. We are currently conducting a clinical trial of mogamulizumab for CCR4‐negative solid cancers (UMIN000010050), specifically aiming to deplete Treg cells.